A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinsons Disease and to a Calibration Arm of Pramipexole ER.
The purpose of this study is to test a new investigational drug for Parkinson's disease.
This study will be conducted at the UBMD Neurology clinic located at 5851 Main St., Williamsville, NY.
Your participation in this study will last approximately 14 to 18 weeks and include about 7 study visits to the study clinic.
No compensation is available.
(CSR#180215181781 ) To determine the superiority of P2B001 0.6/0.75 mg as compared to its individual components in the change of total UPDRS score (defined as sum of parts II and III, scores (0-160).
Male or female ≥35.0 years of age to ≤80.0 years of age
Subject has Parkinson's disease
Subject with disease duration less than 3 years since diagnosis
Let us know how the study team can reach you.
If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email firstname.lastname@example.org and someone will assist you.